UBS downgrades Ontex Group stock rating to Neutral on guidance cut

UBS downgraded Ontex Group NV from Buy to Neutral, significantly cutting its price target to EUR 6.80 from EUR 11.70, following the company's second fiscal year 2025 guidance reduction in under 12 months. This repeated guidance cut has severely diminished UBS's visibility and conviction for Ontex's future volume and EBITDA improvement, raising concerns about investor confidence and limiting its re-rating potential, despite acknowledging progress in leverage reduction and core market EBITDA margin improvement.

Analysis

UBS has downgraded Ontex Group NV to Neutral from Buy, concurrently slashing its price target by 42% to EUR 6.80 from EUR 11.70. The primary catalyst for this revision is Ontex's second reduction in its fiscal year 2025 guidance within a 12-month period, an event that UBS states has severely diminished visibility and conviction in the company's volume and EBITDA growth prospects. Despite the downgrade, UBS acknowledges positive strides in the ongoing turnaround strategy, highlighting a significant reduction in leverage from 6.4x at year-end 2022 to a projected 2.7x by mid-2025, and a near-doubling of core market EBITDA margins to 12.0% in 2024 from 6.2% in 2022. However, these operational improvements are overshadowed by damaged management credibility and a forecasted dip in EBITDA margins to 8.3% in Q2 2025. The core issue identified by UBS is that the repeated failure to meet guidance will likely suppress investor confidence and limit any potential re-rating of the stock over the next year.

Key Decisions for Investors

• Investors should view the sharp price target cut and downgrade as a significant headwind, reflecting a loss of confidence in management's forecasting ability which could cap share price appreciation in the near term.
• Monitor upcoming quarterly reports for strict adherence to the new, lower guidance, as any further misses would severely damage the investment thesis, while consistently meeting targets could begin to rebuild credibility.
• Key metrics to track are the deleveraging progress towards the 2.7x target and the trajectory of EBITDA margins post-Q2 2025, as these will be critical proof points for the underlying health of the turnaround strategy.